Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer

Kinoshita, Yoshihisa; Kuratsukuri, Katsuyuki; Newman, Nancy; Rovito, Peter M.; Kaumaya, P. T.; Wang, C Y; Haas, Gabriel P.

doi:10.1038/sj.pcan.4500835

Cited by 12 publications

(12 citation statements)

References 20 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Xenotransplants of cancer cell lines grown in immune-deficient mice or rats are often considered as counter-parts to poorly differentiated metastases of prostate cancers (14,15). However, poorly differentiated prostate cancer cells in metastases contain cells which still have the ability to produce prostasomes (16,17), but our xenotransplants did not demonstrate any prostasomes-containing cells.…”

Section: Discussionmentioning

confidence: 39%

Mode of Growth Determines Differential Expression of Prostasomes in Cultures of Prostate Cancer Cell Lines and Opens for Studies of Prostasome Gene Expression

Carlsson

Lennartsson

Ronquist

et al. 2006

Upsala Journal of Medical Sciences

View full text Add to dashboard Cite

The exocrine secretion of the acinar gland cells in the human prostate consists of, among other components, a serous secretion and prostasomes. The prostasomes are functionally associated with both reproduction and prostate cancer development and are capable to raise autoantibodies at various pathologies. Therefore, we are trying to characterize prostasome antigens by analysing prostasome-producing cell lines of prostate cancers with the cDNA microarray technique. To obtain one state with synthesis of prostasomes and another state without synthesis, we checked whether the prostasome differentiation was influenced by the mode of growing the cells, that is, whether the cells had been growing on a solid support or on a flexible one.We studied the expression of prostasomes in the cell lines PC3, DU145 and LNCaP. We grew the cells with the following methods: Monocellular layers on microbeads, multicellular spheroids, single cells in suspension cultures, and xenotransplants in nude rats. The presence of prostasomes was examined by ELISA, immunocytochemistry or electron microscopy.The results showed that growing the cells on microbeads (solid support) produced a differentiation of prostasomes, while growing the cells in multicellular spheroids (flexible support) did not. Thus it should be possible to apply cDNA microarray analyses for characterizing the genes which are active at the cellular expression of prostasomes and then deduce the prostasome antigens.

show abstract

Section: Discussionmentioning

confidence: 39%

Mode of Growth Determines Differential Expression of Prostasomes in Cultures of Prostate Cancer Cell Lines and Opens for Studies of Prostasome Gene Expression

Carlsson

Lennartsson

Ronquist

et al. 2006

Upsala Journal of Medical Sciences

View full text Add to dashboard Cite

show abstract

“…Among these 20 genes, six are well‐known androgen‐regulated genes (ARG)—AR, PSMA, HOXB13, NKX3‐1, CITED2, UGT2B15 (Nelson et al , 2002; Velasco et al , 2004)—which have been shown to mediate metastatic disease progression. For example, PSMA (also known as FOLH1), prostate‐specific membrane antigen 1, is used as a diagnostic and prognostic indicator for prostate cancer and is associated with prostate cancer aggressiveness and metastasis (Burger et al , 2002; Schmittgen et al , 2003; Kinoshita et al , 2005). HOXB13, homeobox B13, has been implicated in progression and metastasis in prostate cancer (Jung et al , 2004; Edwards et al , 2005; Zhao et al , 2005) and found to function as an AR repressor, modulating AR signaling (Jung et al , 2004).…”

Section: Resultsmentioning

confidence: 99%

A network biology approach to prostate cancer

Ergün

Lawrence

Kohanski

et al. 2007

Molecular Systems Biology

152

View full text Add to dashboard Cite

There is a need to identify genetic mediators of solid-tumor cancers, such as prostate cancer, where invasion and distant metastases determine the clinical outcome of the disease. Whole-genome expression profiling offers promise in this regard, but can be complicated by the challenge of identifying the genes affected by a condition from the hundreds to thousands of genes that exhibit changes in expression. Here, we show that reverse-engineered gene networks can be combined with expression profiles to compute the likelihood that genes and associated pathways are mediators of a disease. We apply our method to non-recurrent primary and metastatic prostate cancer data, and identify the androgen receptor gene (AR) among the top genetic mediators and the AR pathway as a highly enriched pathway for metastatic prostate cancer. These results were not obtained on the basis of expression change alone. We further demonstrate that the AR gene, in the context of the network, can be used as a marker to detect the aggressiveness of primary prostate cancers. This work shows that a network biology approach can be used advantageously to identify the genetic mediators and mediating pathways associated with a disease.

show abstract

“…In the following years great efforts were undertaken to develop mAbs against the extracellular domain of PSMA. Summarizing these efforts, numerous papers describing in detail the mAbs different characteristics have been published [72][73][74][75][76][77]. Of these, the mAbs J591, J533, J415, D2B, 107-1A4, E99, 3/A12, 3/E7, 3/F11 and 3E6 have been shown to bind the most efficiently to cell-surface PSMA.…”

Section: Antibodiesmentioning

confidence: 99%

Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives

et al. 2020

View full text Add to dashboard Cite

Prostate cancer is the most commonly diagnosed malignancy in men and the second leading cause of cancer-related deaths in Western civilization. Although localized prostate cancer can be treated effectively in different ways, almost all patients progress to the incurable metastatic castration-resistant prostate cancer. Due to the significant mortality and morbidity rate associated with the progression of this disease, there is an urgent need for new and targeted treatments. In this review, we summarize the recent advances in research on identification of prostate tissue-specific antigens for targeted therapy, generation of highly specific and selective molecules targeting these antigens, availability of therapeutic radionuclides for widespread medical applications, and recent achievements in the development of new-generation small-molecule inhibitors and antibody-based strategies for targeted prostate cancer therapy with alpha-, beta-, and Auger electron-emitting radionuclides.

show abstract

Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer

Cited by 12 publications

References 20 publications

Mode of Growth Determines Differential Expression of Prostasomes in Cultures of Prostate Cancer Cell Lines and Opens for Studies of Prostasome Gene Expression

Mode of Growth Determines Differential Expression of Prostasomes in Cultures of Prostate Cancer Cell Lines and Opens for Studies of Prostasome Gene Expression

A network biology approach to prostate cancer

Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives

Contact Info

Product

Resources

About